Treatment with miglustat reverses the lipid-trafficking defect in Niemann–Pick disease type C
- 1 August 2004
- journal article
- case report
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 16 (3), 654-658
- https://doi.org/10.1016/j.nbd.2004.05.002
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Cholesterol Accumulation in NPC1-Deficient Neurons Is Ganglioside DependentCurrent Biology, 2003
- Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement TherapyAnnals of Internal Medicine, 2003
- Substrate reduction therapy for glycosphingolipid storage disordersExpert Opinion on Investigational Drugs, 2001
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Niemann–Pick Type C Mutations Cause Lipid Traffic JamTraffic, 2000
- Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann–Pick C miceJournal of Inherited Metabolic Disease, 2000
- Broad screening test for sphingolipid-storage diseasesThe Lancet, 1999
- Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N -butyldeoxynojirimycinProceedings of the National Academy of Sciences of the United States of America, 1999
- Functional Dissection of COP-I Subunits in the Biogenesis of Multivesicular EndosomesThe Journal of cell biology, 1997
- Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.JCI Insight, 1994